Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)
CNY 18.89
(1.23%)
CNY 18.89
(1.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.09 Billion CNY | -54.76% |
| 2022 | 2.41 Billion CNY | 326.64% |
| 2021 | 567.01 Million CNY | 81.87% |
| 2020 | 311.76 Million CNY | 1267.39% |
| 2019 | 22.8 Million CNY | -7.14% |
| 2018 | 24.55 Million CNY | 80.49% |
| 2017 | 13.6 Million CNY | -38.35% |
| 2016 | 22.06 Million CNY | 18.84% |
| 2015 | 18.56 Million CNY | 62.54% |
| 2014 | 11.42 Million CNY | 12.05% |
| 2013 | 10.19 Million CNY | 215.27% |
| 2012 | 3.23 Million CNY | 67.03% |
| 2011 | 1.93 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 719.61 Million CNY | -8.97% |
| 2024 Q1 | 932.93 Million CNY | -14.76% |
| 2024 Q2 | 790.5 Million CNY | -15.27% |
| 2023 Q2 | 1.62 Billion CNY | -18.76% |
| 2023 FY | 1.09 Billion CNY | -54.76% |
| 2023 Q1 | 2 Billion CNY | -17.14% |
| 2023 Q4 | 1.09 Billion CNY | -17.03% |
| 2023 Q3 | 1.31 Billion CNY | -18.99% |
| 2022 FY | 2.41 Billion CNY | 326.64% |
| 2022 Q4 | 2.41 Billion CNY | 113.1% |
| 2022 Q3 | 1.13 Billion CNY | 6.93% |
| 2022 Q2 | 1.06 Billion CNY | 10.11% |
| 2022 Q1 | 964.22 Million CNY | 70.05% |
| 2021 FY | 567.01 Million CNY | 81.87% |
| 2021 Q4 | 567.01 Million CNY | 53.32% |
| 2021 Q3 | 369.83 Million CNY | 46.48% |
| 2021 Q1 | 391 Million CNY | 25.42% |
| 2021 Q2 | 252.47 Million CNY | -35.43% |
| 2020 Q3 | 279.28 Million CNY | 20.38% |
| 2020 FY | 311.76 Million CNY | 1267.39% |
| 2020 Q1 | 130.64 Million CNY | 473.02% |
| 2020 Q2 | 232 Million CNY | 77.58% |
| 2020 Q4 | 311.76 Million CNY | 11.63% |
| 2019 Q1 | 21.87 Million CNY | -10.89% |
| 2019 Q2 | 26.34 Million CNY | 20.42% |
| 2019 Q4 | 22.8 Million CNY | 3.81% |
| 2019 Q3 | 21.96 Million CNY | -16.64% |
| 2019 FY | 22.8 Million CNY | -7.14% |
| 2018 Q3 | 14.73 Million CNY | -15.6% |
| 2018 Q1 | 10.37 Million CNY | -23.71% |
| 2018 Q2 | 17.45 Million CNY | 68.21% |
| 2018 FY | 24.55 Million CNY | 80.49% |
| 2018 Q4 | 24.55 Million CNY | 66.65% |
| 2017 Q4 | 13.6 Million CNY | 0.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q2 | 13.04 Million CNY | 0.0% |
| 2017 FY | 13.6 Million CNY | -38.35% |
| 2016 Q4 | 20.95 Million CNY | 0.0% |
| 2016 FY | 22.06 Million CNY | 18.84% |
| 2016 Q3 | 20.95 Million CNY | 32.66% |
| 2016 Q2 | 15.79 Million CNY | 0.0% |
| 2016 Q1 | 15.79 Million CNY | -14.93% |
| 2015 Q3 | 17.95 Million CNY | 17.5% |
| 2015 Q2 | 15.28 Million CNY | 0.67% |
| 2015 Q4 | 18.56 Million CNY | 3.41% |
| 2015 FY | 18.56 Million CNY | 62.54% |
| 2015 Q1 | 15.17 Million CNY | 32.88% |
| 2014 Q2 | 31.37 Million CNY | 0.39% |
| 2014 FY | 11.42 Million CNY | 12.05% |
| 2014 Q3 | 11.31 Million CNY | -63.94% |
| 2014 Q1 | 31.24 Million CNY | 206.52% |
| 2014 Q4 | 11.42 Million CNY | 0.98% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q3 | 10.06 Million CNY | 0.0% |
| 2013 Q4 | 10.19 Million CNY | 1.3% |
| 2013 FY | 10.19 Million CNY | 215.27% |
| 2012 FY | 3.23 Million CNY | 67.03% |
| 2011 FY | 1.93 Million CNY | 0.0% |